RxDoctor Payments Data

Ahmed Virani, MD

Pulmonary Disease · Shreveport, LANPI 1881081941

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (49.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Intuitive Surgical at 55.9% of the total. 2025 is the largest year on record at $7,578, more than ten times the $623 reported in 2019.

$11,779in general payments, 2019–2025

Across 178 payments — averaging $66.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • Abiomed$2K
  • AstraZeneca$587
  • Abbott$426
  • Actelion Pharmaceuticals US, Inc.$349
  • Insmed, Inc.$331
  • plus $1K from 14 others

What the payments were for

  • Travel & lodging$9278%
  • Food & beverage$4,97142%
  • Education$5,88150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,779 in reported general payments places this provider in the 80th percentile of 189 pulmonary disease providers in Louisiana.

See all pulmonary disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$186,614
Medicare patients
426
Services billed
1,793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$38,261
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr35$16,447
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$9,692
Breo ElliptaFluticasone/Vilanterol23$8,863
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$1,697
Albuterol Sulfate HfaAlbuterol Sulfate47$1,243
Montelukast Sodium14$78
Prednisone34$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$147$63,571106 claims
Boehringer IngelheimStiolto Respimat$197$9,69219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 189 pulmonary disease providers in Louisiana.

Other pulmonary disease in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →